Funding for this research was provided by:
Received: 4 January 2022
Accepted: 8 April 2022
First Online: 14 May 2022
: The Regional Ethical Review Board of Lund University in Sweden approved the study, and written, informed consent was obtained from all participants according to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.
: Not applicable.
: OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from Roche, Genentech, Siemens, Biogen, Alzpath, and Cerveau. JLD is a minor shareholder of Eli Lilly, received research support (for the institution) from Eli Lilly, and an inventor on the patent application for the Lilly antibodies used in this work. GTB and HK are employees of Janssen Research and Development.